

Supporting Information (SI)

Reduction of Doxorubicin-Induced Cardiotoxicity by Co-Administration of Smart Liposomal Doxorubicin and Free Quercetin: In Vitro and In Vivo Studies

Hamidreza Dorostkar ¹, Bibi Fatemeh Haghirsadat ^{2,3}, Mahdie Hemati ^{1,3}, Fatemeh Safari ^{4,5}, Azam Hassanpour ⁶, Seyed Morteza Naghib ^{7,8}, Mohammad Hossein Roozbahani ⁹, M. R. Mozafari ¹⁰ and Ali Moradi ^{1,*}

¹ Department of Clinical Biochemistry, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd 8916877391, Iran; hr.dorostkar@yahoo.com (H.D.); m.hemati1420@gmail.com (M.H.)

² Department of Advanced Medical Sciences and Technologies, Faculty of Paramedicine, Shahid Sadoughi University of Medical Sciences, Yazd 8916877391, Iran; fhaghirsadat@gmail.com

³ Medical Nanotechnology and Tissue Engineering Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd 8916877391, Iran

⁴ Department of Physiology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd 8916877391, Iran; fa.cardio@gmail.com

⁵ Cardiovascular Research Center, Shahid Sadoughi University of Medical Sciences, Yazd 8916877391, Iran

⁶ Department of Anatomical Sciences, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd 8916877391, Iran; azamhassanpour63@yahoo.com

⁷ Nanotechnology Department, School of Advanced Technologies, Iran University of Science and Technology, Tehran 16846-13114, Iran; naghib@iust.ac.ir

⁸ Biomaterials and Tissue Engineering Department, Breast Cancer Research Center, Motamed Cancer Institute, IUST, ACECR, Tehran 16846-13114, Iran

⁹ School of Advanced Technologies, Iran University of Science & Technology, Tehran 16846-13114, Iran; roozbahani@iust.ac.ir

¹⁰ Australasian Nanoscience and Nanotechnology Initiative (ANNI), Monash University LPO, Clayton, VIC 3168, Australia; dr.m.r.mozafari@gmail.com

* Correspondence: moradi20018@gmail.com; Tel.: +98-9126706056

The full (uncropped) Western blots given below are presented in full in the following pages of this Supplementary Document.




Figure SI.1.a. Western blot bands (Bcl2: ~ 26kDa)




Figure SI.1.b. Densitometry of western blot bands (Bcl2)



Figure SI.2.a. Western blot bands (NOX1: ~ 65kDa)




Figure SI.2.b. Densitometry of western blot bands (NOX1)




Figure SI.3.a. Western blot bands (NOX1: ~ 65kDa)




Figure SI.3.b. Densitometry of western blot bands (NOX1)




Figure SI.4.a. Western blot bands (Rac1: ~ 21kDa)




Figure SI.4.b. Densitometry of western blot bands (Rac1)




Figure SI.5.a. Western blot bands (Rac1-GTP: ~21kDa)




Figure SI.5.b. Densitometry of western blot bands (Rac1-GTP)




Figure SI.6.a. Western blot bands (SIRT3: ~ 28kDa)




Figure SI.6.b. Densitometry of western blot bands (SIRT3)




Figure SI.7.a. Western blot bands (SIRT3: ~ 28kDa)




Figure SI.7.b. Densitometry of western blot bands (SIRT3)




Figure SI.8.a. Western blot bands (b.Actin: ~ 42kDa)




Figure SI.8.b. Densitometry of western blot bands (b.Actin)